NMDA receptors and schizophrenia - PubMed (original) (raw)

Review

NMDA receptors and schizophrenia

Lars V Kristiansen et al. Curr Opin Pharmacol. 2007 Feb.

Abstract

The pathophysiology of schizophrenia is poorly understood but is likely to involve alterations in excitatory glutamatergic signaling molecules in several areas of the brain. Clinical and experimental evidence has shown that expression of the N-methyl-D-aspartate (NMDA) receptor and intracellular NMDA receptor-interacting proteins of the glutaminergic synapse appear to be dysregulated in schizophrenia. It has been suggested that schizophrenia involves molecular changes in the glutamatergic pathways that mediate excitatory communication between multiple brain regions. Recent data also implicate abnormalities in cellular functions such as receptor trafficking and synaptic targeting.

PubMed Disclaimer

Similar articles

• Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
  Javitt DC. Javitt DC. Int Rev Neurobiol. 2007;78:69-108. doi: 10.1016/S0074-7742(06)78003-5. Int Rev Neurobiol. 2007. PMID: 17349858 Review.
• Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
  Yang CR, Chen L. Yang CR, et al. Neuroscientist. 2005 Oct;11(5):452-70. doi: 10.1177/1073858405279692. Neuroscientist. 2005. PMID: 16151046 Review.
• Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
  Pietraszek M. Pietraszek M. Pol J Pharmacol. 2003 Mar-Apr;55(2):133-54. Pol J Pharmacol. 2003. PMID: 12926541 Review.
• Glutamatergic aspects of schizophrenia.
  Tamminga C. Tamminga C. Br J Psychiatry Suppl. 1999;(37):12-5. Br J Psychiatry Suppl. 1999. PMID: 10211134 Review.
• Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia.
  Clinton SM, Haroutunian V, Meador-Woodruff JH. Clinton SM, et al. J Neurochem. 2006 Aug;98(4):1114-25. doi: 10.1111/j.1471-4159.2006.03954.x. Epub 2006 Jun 6. J Neurochem. 2006. PMID: 16762023

Cited by

• Impaired GABAergic neurotransmission in schizophrenia underlies impairments in cortical gamma band oscillations.
  McNally JM, McCarley RW, Brown RE. McNally JM, et al. Curr Psychiatry Rep. 2013 Mar;15(3):346. doi: 10.1007/s11920-012-0346-z. Curr Psychiatry Rep. 2013. PMID: 23400808 Free PMC article. Review.
• The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders.
  Kosowski M, Smolarczyk-Kosowska J, Hachuła M, Maligłówka M, Basiak M, Machnik G, Pudlo R, Okopień B. Kosowski M, et al. Molecules. 2021 May 11;26(10):2838. doi: 10.3390/molecules26102838. Molecules. 2021. PMID: 34064670 Free PMC article. Review.
• NAAG, NMDA receptor and psychosis.
  Bergeron R, Coyle JT. Bergeron R, et al. Curr Med Chem. 2012;19(9):1360-4. doi: 10.2174/092986712799462685. Curr Med Chem. 2012. PMID: 22304714 Free PMC article. Review.
• A Selective Review of the Excitatory-Inhibitory Imbalance in Schizophrenia: Underlying Biology, Genetics, Microcircuits, and Symptoms.
  Liu Y, Ouyang P, Zheng Y, Mi L, Zhao J, Ning Y, Guo W. Liu Y, et al. Front Cell Dev Biol. 2021 Oct 21;9:664535. doi: 10.3389/fcell.2021.664535. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34746116 Free PMC article. Review.
• Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat.
  Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, Bifone A. Gozzi A, et al. Psychopharmacology (Berl). 2008 Dec;201(2):273-84. doi: 10.1007/s00213-008-1271-z. Epub 2008 Aug 15. Psychopharmacology (Berl). 2008. PMID: 18704372

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information